How Pharma Stocks Reacted To Trump's 200% Tariff Threat On Generic Drugs
US President Donald Trump announced a phased tariff imposition on generic drugs, including 100% tariffs from August 1, 2026, rising to 200%.
The Nifty Pharma index fell nearly 2% on July 22, 2026, with all constituents trading lower.
Lupin, Gland Pharma, Aurobindo Pharma, Ajanta Pharma, Sai Life Sciences, and Zydus Lifesciences shares fell over 2% each.
The tariffs aim to encourage generic drug manufacturers to establish production facilities in the US, with higher penalties for those that fail to relocate.
India supplies 40% of generic drugs imported by the US, and manufacturing a generic drug in India costs 30–50% less than in the US.
Story angle
Right lean
Framed from a right-leaning view: often supportive of government, security, or traditional positions.
About how the story is framed, not whether the facts are true.
Republic World
Right leaning
Low factuality
Who owns this?
ARG Outlier Media
Arnab Goswami
Founded in 2017; known for opinion-forward prime time.
Wikipedia: Arnab Goswami